Sharon nachman, md

Dr. Sharon Nachman is a scientist and clinical investigator with more than 25 years of continuous NIH support (U mechanism from the IMPAACT network) dedicated to developing and implementing clinical therapeutic trials for infants, children, adolescents and pregnant women. She has had leadership roles in over 25 clinical trials developed through our network, including 20 as either protocol chair or vice chair. All studies have enrolled, analyzed, and published results that have changed the way we evaluate and treat HIV infected and exposed children and women worldwide. While much of my work has centered around these populations, She has also developed studies helping to define the dose and PK for new antibiotics, evaluate new vaccines and understand the long term issues that develop in infants born to HIV+ women worldwide.

With the COVID-19 pandemic epicenter in New York, and as Chair of the Stony Brook Medicine’s COVID Research Committee, Dr. Nachman has been at the front lines of care and research for patients with COVID-19. She is currently serving as the PI of a novel therapeutics study “Phase II Clinical Trial of Estradiol to reduce severity of COVID19 infection in COVID19+ and Presumptive COVID19+ Patients”, opened and enrolling at our institution. https://clinicaltrials.gov/ct2/show/NCT04359329?term=estrogen&cond=COVID&draw=2 . She is the PI for the NIH NOSI funded IMPAACT Study 2032: Safety and PK of Remdesivir in pregnant and non pregnant women.

ABSTRACT

COVID-19 NIAID’s Clinical Trial Plans

Dr. Nachman will give attendees an update on what is being developed by NIAID with regard to COVID-19 clinical trials; treatment, prevention and vaccines.